SFM
VRTX icon

Sphera Funds Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Sphera Funds Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,000
Closed -$1.91M – 145
2014
Q2 		$1.91M Buy
1,000
+500
+100% +$35.1K 0.47% 52
2014
Q1 		$543K Buy
+500
New +$39.6K 0.12% 102

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sphera Funds Management's VRTX Position: Q1 2022 in Review

Sphera Funds Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2022, closing a stake of 4,411 shares — an estimated $969K sold.

Sphera Funds Management first reported a position in VRTX in Q1 2014 and held it in 13 quarters. The position peaked at $16.8M in Q3 2014. 1,072 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

  • Sphera Funds Management reported no remaining Vertex Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Sphera Funds Management sold 4,411 Vertex Pharmaceuticals shares in Q1 2022, an estimated $969K.
  • Sphera Funds Management first reported a position in Vertex Pharmaceuticals in Q1 2014 and held it in 13 quarters.
  • Sphera Funds Management's Vertex Pharmaceuticals position peaked at $16.8M in Q3 2014.
  • 1,072 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Sphera Funds Management's 13F filing for Q1 2022, filed 16 May 2022.